Can meibomian glands grow back?

The honest answer is that no treatment has been shown to regrow meibomian glands that have genuinely been lost, and anyone who tells you otherwise is going beyond the evidence. What can change is how well the glands you still have are working, and that is where nearly all of the benefit of treatment sits.

There is one more thing worth knowing, and it is the reason this question is not as bleak as it first sounds. A meibography image showing gaps where glands should be is not always showing dead tissue. Some of those glands are obstructed and distorted rather than gone, and a small study has reported that measured gland dropout can decrease slightly with treatment. "Slightly" is doing real work in that sentence, and the rest of this article explains why.

If you have just been shown a scan of your own lids and told that a third of your glands are missing, that is a hard thing to hear. It is also not a countdown. Most people with visible gland loss do well with treatment, because comfort tracks how well the remaining glands deliver far more closely than it tracks how many are visible on an image.

What meibography actually shows

Infrared meibography lights up the glands inside an everted eyelid as pale finger-like structures against a darker tarsal plate. Arita's widely used grading scores each lid from 0, no loss, through 3, more than two-thirds of the gland area lost, and the two lids are summed for a score out of 6.

That study is worth understanding before you interpret your own image, because it was done in a normal population: 236 healthy volunteers aged 4 to 98, not a dry eye clinic. The score rose significantly with age in men and women alike, and correlated with lid margin abnormality. Some visible gland loss is an ordinary feature of getting older, not proof that something has gone wrong. Our article on what meibography shows covers how to read an image in more detail.

What meibography cannot do is tell you why a gland looks short or absent. It is a picture of structure, not of function, and the two come apart in both directions. Glands can look intact and deliver nothing. Glands can look shortened and still contribute.

Missing, or blocked and distorted?

This distinction matters more than any other in the whole discussion. The MGD workshop's anatomy report describes what happens inside an obstructed gland: the terminal duct narrows as its lining thickens with keratin, secretion backs up, the gland dilates, and only then does it become atrophic with fewer secretory acini. Obstruction comes first. Atrophy is the late consequence.

A gland partway along that path can look abnormal on meibography — dilated, distorted, shortened, or hard to make out against its neighbours — while still containing living secretory tissue. Blackie and colleagues made the related point from the clinical side: in the form they named nonobvious obstructive meibomian gland dysfunction, the classic signs are often absent altogether unless the examiner deliberately expresses the glands, and treatment succeeds only when the obstruction is relieved.

So there are two questions your optometrist is really asking, and only one of them is answered by the picture:

• How much gland structure is left? Meibography answers this, imperfectly.
• How much of what is left is delivering oil? Only expression answers this, and it is the question that predicts how you will feel.

What the reversibility study actually found

Yin and Gong published the study people usually mean when they say gland loss can be reversed. It deserves to be quoted accurately rather than hopefully.

It was a retrospective review of 78 eyes of 78 patients with stage 2 to 3 MGD who completed follow-up after one month of treatment. Everyone was given artificial lubricant and instructed in eyelid hygiene. Twenty-six patients, a third of the group, did not follow the eyelid hygiene instruction; the other 52 did. In the group that ignored it, only the symptom score improved. In the compliant group every clinical measure improved except the Schirmer test, expressibility included. And in that compliant group the authors observed a decrease in gland dropout of about 5% — 5.4% in the upper lids and 4.6% in the lower. Improvement in upper-lid dropout and in expressibility predicted improvement in lower-lid dropout, and the change was not related to age, sex, pretreatment stage, how long the patient had been ill, or whether they used anti-inflammatory drops.

The authors' own conclusion was measured: with expressibility-improving treatment, gland dropout was reversible to some extent.

What that is not is a demonstration of regrowth. The study was retrospective and uncontrolled, ran for a single month, and measured dropout as an area on an infrared image. There is a simpler reading available, and the study cannot rule it out. A gland that decompresses and refills after its duct is cleared will occupy more of that image than it did when it was collapsed and obstructed, without a single new acinus having formed. A 5% shift in a measured area over four weeks is consistent with that explanation, and nothing in a one-month retrospective series separates the two. It is an encouraging result and a small one — small enough to sit inside the range over which experienced graders disagree with each other on the same images — and it is the strongest thing in this literature.

Why treating early matters

Read the sequence in the anatomy report again and the practical argument writes itself. Obstruction precedes atrophy. Every month a gland spends obstructed is a month it spends on the path towards losing acini, and the tissue lost at the end of that path is the part nobody can promise to give back.

That is the real case for not waiting. Not that treatment restores what has gone, but that it protects what has not. The workshop's staged treatment algorithm starts at the mildest stage with eyelid warming, hygiene and expression precisely because that is the point where the intervention is cheap and the glands are still there to save. Our guide to the stages of MGD sets out where you might sit.

Protecting the glands you have

In practice this means keeping the ducts clear, consistently, for as long as you have the condition. Heat comes first because meibum has to be warm enough to flow before anything else works; the management report specifies continuous 45 °C compresses for at least four minutes, replaced every two minutes with a preheated one to hold that temperature. Warming is followed by lid hygiene and, if your optometrist has taught you the technique, gentle expression against the lid margin rather than into the eyeball. There is more in how to unblock meibomian glands and in our overview of what MGD is.

Consistency matters more than intensity. The Yin and Gong groups differed only in whether patients actually did the lid hygiene they were told to do, and that single difference separated a group where one measure improved from a group where nearly everything did. Whatever routine you adopt, the one that works is the one you keep doing.

If you have an active eye infection, have had eye surgery recently, have glaucoma, or notice any change in your vision, speak to your optometrist or ophthalmologist before starting heat therapy or continuing with it.

Doing that daily for years is easier when the heat step is a fixed setting and a fixed timer rather than a judgement call each night. The Meibocare E-Heated Eye Mask is designed to bring the eyelids to about 42 °C on the recommended setting and timer, using a graphene heating element with flaxseed filling, its three settings each paired to a timer — 20 minutes on Low, 15 on Medium, 10 on High. It is notified to Medsafe on the New Zealand WAND database (240927-WAND-746QNT), a register that records notification rather than assessing the device, and is the test device in a registered randomised trial at the University of Auckland (ACTRN12625000997459). It is a way of keeping the routine going, not a way of getting lost glands back.

Frequently asked questions

Can meibomian glands grow back?

No treatment has been shown to regrow meibomian glands that have truly been lost. One retrospective study of 78 eyes reported that measured gland dropout fell by about 5% after a month of eyelid hygiene in compliant patients, and the authors described dropout as reversible to some extent. That is a small, uncontrolled finding and is not evidence of regeneration.

Is meibomian gland atrophy permanent?

Treat true atrophy as permanent when planning your care, because nothing has been shown to reverse it. What is not permanent is obstruction. Glands that look shortened or absent on meibography may be blocked and distorted rather than gone, and clearing them can restore oil delivery without changing the image much at all.

Does gland loss mean my dry eye will keep getting worse?

Not necessarily. How you feel tracks how well your remaining glands deliver oil far more closely than it tracks how many glands are visible on a scan. Some gland loss is also a normal part of ageing, and was found to increase with age in a study of 236 healthy volunteers aged 4 to 98.

How do I stop losing more meibomian glands?

Keep the ducts clear. Obstruction precedes atrophy, so the glands most at risk are the ones blocked right now. Guideline treatment starts with daily eyelid warming, lid hygiene and, where taught, gentle expression. Consistency matters more than intensity, and an examination will tell you whether your current routine is actually working.

Educational information only, not medical advice. References: Arita R, et al. Ophthalmology. 2008;115:911–915; Knop E, et al. Invest Ophthalmol Vis Sci. 2011;52:1938–1978; Blackie CA, et al. Cornea. 2010;29:1333–1345; Yin Y, Gong L. Cornea. 2017;36:332–337; Geerling G, et al. Invest Ophthalmol Vis Sci. 2011;52:2050–2064; Nichols KK, et al. Invest Ophthalmol Vis Sci. 2011;52:1922–1929.